Skip to content Skip to footer
VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…

Read more

Viewpoints_Carsten Linnemann

Carsten Linnemann, CEO at Neogene Therapeutics Shares Insights on the Approval of CTA for the P-I Trial of its TCR Therapy to Treat Solid Tumors

Carsten spoke about the approval of CTA by the Dutch regulatory authority for a P-I study evaluating its TCR therapy for the treatment of solid tumorsCarsten also emphasized how NT-125 will be different from other TCR therapiesThe interview shows the advancement of Neogene’s pipeline developing transformative TCR therapies targeting neoantigens in solid cancers…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]